LACK OF CORRELATION BETWEEN MATERNAL ANTIBODIES TO V3 LOOP PEPTIDES OF GP120 AND PERINATAL HIV-1 TRANSMISSION

被引:82
作者
PAREKH, BS
SHAFFER, N
PAU, CP
ABRAMS, E
THOMAS, P
POLLACK, H
BAMJI, M
KAUL, A
SCHOCHETMAN, G
ROGERS, M
GEORGE, JR
机构
[1] HARLEM HOSP MED CTR,NEW YORK,NY
[2] NEW YORK CITY DEPT HLTH,NEW YORK,NY 10013
[3] BELLEVUE HOSP CTR,NEW YORK,NY 10016
[4] METROPOLITAN HOSP CTR,NEW YORK,NY 10029
[5] LINCOLN HOSP,NEW YORK,NY
关键词
PERINATAL HIV-1 TRANSMISSION; GP120; V3; LOOP; PRINCIPAL NEUTRALIZING DETERMINANT; HIGH-AFFINITY ANTIBODIES;
D O I
10.1097/00002030-199110000-00004
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Recent reports have suggested that maternal antibodies to specific epitopes of the variable region 3 (V3 loop) of gp120 of HIV-1 might protect against perinatal transmission. in an attempt to confirm these findings, sera from 34 HIV-1-seropositive mothers, representing 13 episodes of mother-to-infant transmission and 23 episodes of non-transmission (two mothers had two pregnancies each during the study period), were tested for the presence of antibodies to various regions of the gp120 V3 loop. Synthetic peptides were generated from HIV-1MN. Of the four peptides tested by enzyme-linked immunosorbent assay (ELISA), only antibody to the C53 peptide (Env310-322, principal neutralizing determinant) was present in maternal sera. Antibody to the C53 sequence was present in 11 specimens from transmitting mothers and 21 from non-transmitting mothers (84.6 and 91.3%, respectively, P = 0.6). No reactivity was detected against the C51, C57, or C58 peptide sequences, located on the sides of the V3 loop. In an antigen-limited ELISA, only two specimens from transmitting mothers and two specimens from non-transmitting mothers had detectable 'high-affinity' antibodies to C53 at low antigen concentrations (15.4 and 8.7%, respectively; P = 0.6). Our results do not support previous reports that epitope-specific antibodies to the V3 loop peptides protect against perinatal transmission. Further research is required to determine whether any specific maternal humoral response might influence HIV-1 perinatal transmission.
引用
收藏
页码:1179 / 1184
页数:6
相关论文
共 28 条
[1]  
BOTTIGER B, 1988, CLIN EXP IMMUNOL, V73, P339
[2]   DIAGNOSTIC-IMPLICATION OF SPECIFIC IMMUNOGLOBULIN-G PATTERNS OF CHILDREN BORN TO HIV-INFECTED MOTHERS [J].
BROLIDEN, PA ;
MOSCHESE, V ;
LJUNGGREN, K ;
ROSEN, J ;
FUNDARO, C ;
PLEBANI, A ;
JONDAL, M ;
ROSSI, P ;
WAHREN, B .
AIDS, 1989, 3 (09) :577-582
[3]   CURRENT AND FUTURE DIMENSIONS OF THE HIV AIDS PANDEMIC IN WOMEN AND CHILDREN [J].
CHIN, J .
LANCET, 1990, 336 (8709) :221-224
[4]   VERTICAL TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS IS CORRELATED WITH THE ABSENCE OF HIGH-AFFINITY AVIDITY MATERNAL ANTIBODIES TO THE GP120 PRINCIPAL NEUTRALIZING DOMAIN [J].
DEVASH, Y ;
CALVELLI, TA ;
WOOD, DG ;
REAGAN, KJ ;
RUBINSTEIN, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (09) :3445-3449
[5]   ANTIBODY-MEDIATED INVITRO NEUTRALIZATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ABOLISHES INFECTIVITY FOR CHIMPANZEES [J].
EMINI, EA ;
NARA, PL ;
SCHLEIF, WA ;
LEWIS, JA ;
DAVIDE, JP ;
LEE, DR ;
KESSLER, J ;
CONLEY, S ;
MATSUSHITA, S ;
PUTNEY, SD ;
GERETY, RJ ;
EICHBERG, JW .
JOURNAL OF VIROLOGY, 1990, 64 (08) :3674-3678
[6]  
GOEDERT JJ, 1989, LANCET, V2, P1351
[7]   HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 NEUTRALIZATION EPITOPE WITH CONSERVED ARCHITECTURE ELICITS EARLY TYPE-SPECIFIC ANTIBODIES IN EXPERIMENTALLY INFECTED CHIMPANZEES [J].
GOUDSMIT, J ;
DEBOUCK, C ;
MELOEN, RH ;
SMIT, L ;
BAKKER, M ;
ASHER, DM ;
WOLFF, AV ;
GIBBS, CJ ;
GAJDUSEK, DC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (12) :4478-4482
[8]  
HALSEY NL, 1991, 7 INT C AIDS FLOR
[9]   PRINCIPAL NEUTRALIZING DOMAIN OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 ENVELOPE PROTEIN [J].
JAVAHERIAN, K ;
LANGLOIS, AJ ;
MCDANAL, C ;
ROSS, KL ;
ECKLER, LI ;
JELLIS, CL ;
PROFY, AT ;
RUSCHE, JR ;
BOLOGNESI, DP ;
PUTNEY, SD ;
MATTHEWS, TJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (17) :6768-6772
[10]  
LAROSSA G, 1989, VACCINES 90 MODERN A, P277